Aflibercept

Case Study:

Phase I Ophthalmology Trial (Aflibercept)

Therapeutic Area:

Ophthalmology – Retinal Disorders

Study Phase:

Phase I | International | Full-Service CRO Support

Client Challenge:

Aflibercept, a therapeutic agent for retinal disorders including age-related macular degeneration, required an experienced CRO to fully manage an international Phase I trial—from early study concept through final Clinical Study Report (CSR). The sponsor sought a partner capable of handling complex operational execution, regulatory rigor, and technically demanding pharmacokinetic (PK) assessments in an early-phase setting.

Smooth Drug Development Full-Service Solution:

Smooth Drug Development provided end-to-end CRO services, supporting the study across its entire lifecycle:

• Study concept development and operational planning

• Regulatory strategy and submissions

• Site feasibility, activation, and start-up

• Clinical monitoring and site management

• Pharmacokinetic coordination and bioanalytical oversight

• Data management and medical writing

• Final Clinical Study Report (CSR) development

The study was conducted over a 7-month period, with a strong focus on quality, compliance, and transparent collaboration with the sponsor.

Key Operational & Scientific Challenges:

Site Readiness & Recruitment Risk:

• Equipment discrepancies identified during site initiation

• Overestimated recruitment projections requiring mitigation

Complex PK Assessment:

• Extremely low drug concentrations in systemic circulation

• Initial analytical methods insufficient for plasma detection

Proactive & Collaborative Approach:

Smooth Drug Development applied a risk-based, solution-driven CRO model:

• Rapid site reassessment and corrective actions

• Activation of two additional sites to protect enrollment timelines

• Close collaboration with sponsor and bioanalytical partners

• Successful validation of a sensitive PK method enabling drug identification in plasma

Results & Outcomes:

• End-to-end study delivery from concept to CSR

• Enrollment targets achieved without protocol deviations

• Preserved timelines and full GCP compliance

• 100 patients were enrolled in the study

• 4 study sites were initiated

Why Smooth Drug Development:

Smooth Drug Development delivers strategic partnership, scientific rigor, and proactive risk management—supporting sponsors from study concept to CSR, even in the most complex early-phase clinical programs.